Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Thursday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.29 on Thursday. The stock has a fifty day moving average price of $0.35 and a 200-day moving average price of $0.97. The company has a market cap of $3.57 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $7.74.

Institutional Trading of Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.